House Bill 2163
Senate Amendments
Section-by-Section Analysis

HOUSE VERSION	SENATE VERSION	CONFERENCE
SECTION 1. Subchapter B, Chapter 531, Government Code, is amended by adding Section 531.0731 to read as follows: Sec. 531.0731. STUDY REGARDING THE PROVISION OF CERTAIN MEDICATION TO CHILDREN. (a) The commission shall conduct a study to determine the appropriateness and safety of providing antipsychotic or neuroleptic medication through the Medicaid vendor drug program to children younger than 16 years of age. (b) The study conducted under Subsection (a) must consider the following factors relevant to the appropriateness and safety of providing the medications to children: (1) the physical and psychological medical diagnosis of a child's condition; (2) whether the United States Food and Drug Administration has approved a medication for use by a child of a certain age; (3) whether a child has successfully taken a medication previously; (4) access to quality medical care for a child receiving benefits under the program; (5) the standard of care in the medical profession regarding the provision of such medications to a child; and (6) any other factor the commission considers relevant. (c) Not later than November 10, 2010, the executive commissioner shall submit a report containing the results	Same as House version.	

HOUSE VERSION	SENATE VERSION	CONFERENCE
of the study conducted under Subsection (a) to the governor, the lieutenant governor, the speaker of the house of representatives, and the chairs of the Senate Committee on Health and Human Services and the House Committee on Public Health.		
No equivalent provision.	SECTION __. (a) In this section, "pharmacy care management services" means services provided by a pharmacy to support patients receiving treatment or therapy through a specialty pharmacy drug or therapy and maximize adherence to the drug or therapy, including: (1) significant caregiver and provider contact and education regarding the relevant disease, disease prevention and treatment, and counseling related to drug indications, benefits, risks, complications, and appropriate use of the prescribed drug or therapy; (2) patient compliance services, including coordination of provider visits with delivery of the specialty drug or therapy to the provider, compliance with the dosing regimen, patient reminders, compilation of data, and assisting providers in the development of compliance programs; and (3) tracking services, including developing ordering processes with a provider, screening referrals, and tracking a patient's weight for dosing requirements. (b) The Health and Human Services Commission shall study the feasibility of establishing separate	

HOUSE VERSION	SENATE VERSION	CONFERENCE
	reimbursement rates under the Medicaid vendor drug program for pharmacies that provide pharmacy care management services to patients who are administered specialty pharmacy drugs, including drugs indicated for the prophylaxis of respiratory syncytial virus, blood factor, or any other biologic or therapy that requires complex care. (c) In conducting the study under Subsection (b) of this section, the Health and Human Services Commission shall consult with the Centers for Medicare and Medicaid Services and may consider the adoption of pharmacy care management services reimbursement for pharmacy services adopted by other state Medicaid programs. (d) The Health and Human Services Commission shall seek information from specialty pharmacy providers or other sources regarding the costs of providing pharmacy care management services. (e) Not later than September 1, 2010, the Health and Human Services Commission shall submit a written report of the results of the study conducted under Subsection (b) of this section to the legislature.	
SECTION 2. This Act takes effect September 1, 2009.	Same as House version.	